Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III clinical trial to investigate AST-VAC1 for the treatment of acute myelogenous leukaemia

Next Previous
Trial Profile

A phase III clinical trial to investigate AST-VAC1 for the treatment of acute myelogenous leukaemia

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VAC 1 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Asterias Biotherapeutics

    • Most Recent Events

    • 04 Nov 2016 According to an Asterias Biotherapeutics media release, company will commenced this trial in 2018.
    • 24 Feb 2016 According to an Asterias Biotherapeutics media release, the results from this trial may support an accelerated development pathway and Biologics License Application (BLA) filing. Asterias plans to submit a request for a Special Protocol Assessment (SPA) to the FDA to confirm the primary endpoint and other design elements of this trial.
    • 12 Aug 2015 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top